Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

(2021) Enrico Franceschi et al.   Diagnostics

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

(2021) C. Mircea S. Tesileanu et al.   ACTA NEUROPATHOLOGICA

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

(2021) Ingo K. Mellinghoff et al.   CLINICAL CANCER RESEARCH

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

(2021) Jorge E. Cortes et al.   BLOOD

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

(2020) Jorge E. Cortes et al.   BLOOD

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

(2020) Justin M. Watts et al.   BLOOD

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor

(2020) Justin A. Caravella et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

(2020) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma

(2019) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients

(2019) Christina K. Cramer et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

2-Hydroxyglutarate in Cancer Cells

(2019) Petr Ježek   ANTIOXIDANTS & REDOX SIGNALING

Wild-type and mutated IDH1/2 enzymes and therapy responses

(2018) Remco J. Molenaar et al.   ONCOGENE

Current Challenges and Opportunities in Treating Glioblastoma

(2018) Andrea Shergalis et al.   PHARMACOLOGICAL REVIEWS

Mutant IDH1 Promotes Glioma Formation In Vivo

(2018) Beatrice Philip et al.   Cell Reports

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

(2018) Justin M. Watts et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary brain tumours in adults

(2018) Sarah Lapointe et al.   LANCET

IDH1: Linking Metabolism and Epigenetics

(2018) Silvia Raineri et al.   Frontiers in Genetics

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

(2017) Benjamin M. Ellingson et al.   Neurotherapeutics

NADPH: new oxygen for the ROS theory of aging

(2016) Pablo J. Fernandez-Marcos et al.   Oncotarget

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

IDH1 and IDH2 Mutations in Gliomas

(2013) Adam L. Cohen et al.   Current Neurology and Neuroscience Reports

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms

(2013) Dinesh Rakheja et al.   Frontiers in Oncology

The efficacy of temozolomide for recurrent glioblastoma multiforme

(2012) Chao Chen et al.   EUROPEAN JOURNAL OF NEUROLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation of gliomas with long-term survival analysis

(2012) JAE KYUNG MYUNG et al.   ONCOLOGY REPORTS

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

(2011) MJ van den Bent et al.   LANCET ONCOLOGY

Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism

(2010) Z. J. Reitman et al.   JNCI-Journal of the National Cancer Institute

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE